My experience with Bipicar: a simple puncture led to months of complaints, a €753.99 charge that was never refunded, and a consumer arbitration case closed without resolving the dispute.
@bipi_Es@ComunidadMadrid#Bipi#Bipicar https://t.co/kqots3HPnp
Mi experiencia con Bipicar: un simple pinchazo terminó en meses de reclamaciones, un cargo de 753,99 € que nunca me devolvieron y un arbitraje cerrado sin resolver el fondo del conflicto.
@bipi_Es@ComunidadMadrid#Bipi#Bipicar https://t.co/36aMq4avcc
Mi hijo me preguntó por qué Messi, después de tirar a Merino al suelo de una patada, siguió caminando como si nada y ni siquiera lo miró. Me dejó sin respuesta. Muchos hablan de un supuesto favoritismo hacia Argentina, pero lo que más me sorprende es que a una leyenda como Messi le resulte tan difícil mostrar un mínimo gesto de deportividad.
이유는 간단합니다.
중국인 아무나 붙잡고 물어봐도 “A주는 웬만하면 건드리지 마라”라고 말할 겁니다.
그런데도 직접 분석하고 조사한 뒤에 “이번엔 다르다”며 들어간 전문 투자자가 있었다는 사실 자체가 뉴스거리인 거죠.
참고로 비슷한 수업료를 냈던 유명한 선배가 한 명 있습니다.
이름은 레이 달리오(Ray Dalio) 입니다. 😅
His real profits aren’t from the market — they’re from selling courses. The tickers are just props.
That “90% position”? I believe it — because it might only be 100 shares.
Anyone can claim they were an early NVIDIA holder — no verification required.
Bottom line: every symbol he promotes is part of the funnel. The end goal is the course.
@CMDarnton0 I agree with most of your thesis. What I struggle with is Andrew repeatedly unloading shares near peaks — he’s starting to look like the market’s lead bear on his own stock. That kind of short-term signaling makes it difficult to frame this company as a true disruptor.
The $NVO lawsuit and possible FDA action don’t concern me nearly as much.
The real risk is the calendar — it’s Andrew selling season again.
That’s $HIMS actual black swan event.
I’ve been trying to understand everything that happened this week, and I can actually find quite a few things that make sense. The biggest contradiction, though, is that Andrew is one of the very few CEOs who repeatedly cashed out at the highs — which is why some people say he’s the $HIMS biggest short.
Tonight, when our ad airs during the Big Game, we will continue a much-needed conversation around what healthcare should look and feel like in America: affordable, proactive, personalized.
When we start hard conversations, we expect challenges along the way. But we won't ever stop advocating for better until the system becomes better for everyone.
https://t.co/iXmFwEkw0N
Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.
https://t.co/rhsmDXFh9g